Wednesday, 3 December 2025
HELIX alpha, an investment manager focused on life science real assets, has appointed four new members to its advisory board, strengthening the company’s strategic competence across science, real estate and investment management. The newly formed body brings together international and interdisciplinary expertise to support decision-making in a sector that is both technical and highly specialized.
The advisory board will be chaired by Prof. Dr. Thomas Glatte, CEO of Familienheim Rhein-Neckar and Professor of Real Estate Management. He previously spent nearly two decades as Director Global Real Estate at BASF, giving him extensive insight into life-science user requirements. His work with the BASF pension fund also provides experience with institutional investor perspectives.
Dr. Inez de Greef, Managing Partner at 3D-PharmXchange and CEO of biotechnology company Treeway, joins the board with a background in research, drug development and science-driven innovation, expertise considered essential for evaluating the long-term suitability of locations and tenants in the life science sector.
Dr. Thomas Diefenthal, Managing Director of BioPark Regensburg and former Vice President of the Federal Association of German Innovation, Technology, and Start-up Centers, adds knowledge of European life science parks and cluster development, as well as broader sector dynamics.
Prof. Dr. Andreas Pfnür, Head of the Real Estate and Construction Management Department at TU Darmstadt, contributes economic and academic expertise, with a focus on corporate real estate and life science real estate. His connections to major pharmaceutical companies further complement the board’s profile.
The members will not serve solely in an advisory role. They have been integrated directly into the firm’s governance framework as voting members of the “Investment & Risk Committee”. As part of this committee, they will participate in shaping investment policy and reviewing key investment decisions, including acquisitions and portfolio assessments. HELIX alpha states that this approach is designed to ensure that its strategies address the technical, scientific, regulatory and strategic complexities of the life science real estate asset class.
“We are not investing in buildings – we are investing in complex ecosystems,” said Martin Eberhardt FRICS, Founder and CEO of HELIX alpha. “This requires a deep understanding of the life science sector, its user needs, and the requirements of locations and regulation. This is precisely the expertise the advisory board adds—and it is crucial for sustainable performance in this young and complex asset class.”
HELIX alpha aims to develop a diversified portfolio across major European life science clusters, including Barcelona, Copenhagen, Vienna and Cambridge, with properties spanning laboratory, production and logistics facilities.
